Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
guselkumab + methotrexate
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral, Intramuscular
01
Overview
Guselkumab (CNTO 1959) is a fully human immunoglobulin G1 lambda monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), blocking its interaction with the IL-23 receptor and inhibiting downstream signaling and cytokine production. This mechanism reduces inflammation associated with autoimmune diseases. Guselkumab is primarily indicated for plaque psoriasis and psoriatic arthritis and has also been studied in ulcerative colitis. Methotrexate is a small molecule antimetabolite that inhibits dihydrofolate reductase (DHFR), interfering with DNA synthesis and cell replication; it is used to treat various cancers as well as autoimmune conditions such as rheumatoid arthritis and severe psoriasis. The combination of guselkumab plus methotrexate has been investigated for enhanced efficacy in inflammatory diseases such as psoriatic arthritis[3][5][6][7].
- Brand names
- TremfyaTrexallXatmepJylamvo
- Other names
- CNTO 1959CNTO1959CNTO-1959guselkumabmethotrexate
02
Targets
DHFR (Dihydrofolate reductase)IL23A (Interleukin-23 p19 Subunit)
Beyond the preview
Go deeper on guselkumab + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on guselkumab + methotrexate.